Optovue, Inc. Company Profile

08:10 EDT 18th September 2019 | BioPortfolio

Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercialization of high-speed OCT and OCTA technology used to facilitate the diagnosis and management of eye diseases, many of which may lead to permanent blindness. Optovue is the first company to develop and commercialize the pioneering OCTA technology. To date, there are over 225 peer-reviewed publications detailing the AngioVue Imaging technology and clinical applications. The company has installed over 11,000 products worldwide and employs over 170 people. For more information, visit

News Articles [2 Associated News Articles listed on BioPortfolio]

Optovue launches new AngioWellness scan

The AngioWellness scan utilizes Optovue’s advanced AngioVue® OCTA technology to quickly assess and diagnose new pathologies in patients, including diabetic patients and those who may be at risk...

Ping An concludes clinical study for world’s first OCT retinal disease screening system

Ping An Technology, along with Optovue, has developed the first artificial intelligence (AI) imaging and screening system, which seamlessly incorporates an OCT retinal imaging device and AI lesion Th...

Drugs and Medications [0 Results]


PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Repeatability and Agreement of Macular Thickness Measurements Obtained with Two Different Scan Modes of the Optovue RTVue Optical Coherence Tomography Device

To evaluate the repeatability and agreement of macular thickness measurements obtained with E-MM5 and MM6, two different scan modes, on the Optovue RTVue optic coherence tomography (OCT) device.

Projection resolved optical coherence tomography angiography to distinguish flow signal in retinal angiomatous proliferation from flow artifact.

To investigate whether hyperreflective foci (HRF) exhibit flow projection artifact on OCTA, and study the efficacy of commercial projection artifact removal software (PAR-OCTA, Optovue, Inc), and a cu...

Macular retinal thickness and flow density change by optical coherence tomography angiography after posterior scleral reinforcement.

Optical coherence tomography angiography (Angio-OCT) has introduced a new non-invasive, quantitative method to assess superficial and deep capillary networks of the retina. In this study, we investiga...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.

Corneal and Anterior Segment Optical Coherence Tomography - Optovue

The objective of the study is to further develop clinical applications for the high speed corneal and anterior segment optical coherence tomography (CAS-OCT) system developed by Optovue, I...

Repeatability, Reproducibility and Comparison of Cirrus OCT, RTVue OCT, MS-39 OCT, and Insight 100 VHFDU

The purpose of this study is to evaluate the repeatability and reproducibility of corneal, epithelial, and LASIK flap thickness using the Carl Zeiss Meditec Cirrus HD OCT 5000, Optovue RTV...

Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound

The purpose of this study is to assess the repeatability, reproducibility, and agreement of central corneal thickness measured by Fourier Domain Optical Coherence tomography (FD-OCT, OptoV...

Evaluation of RTVue XR With SSADA

Optovue has implemented a motion contrast imaging software in RTVue XR, a split spectrum amplitude decorrelation algorithm (SSADA), for non-invasive imaging of ocular vasculature. Consente...

Companies [3 Associated Companies listed on BioPortfolio]

Optovue, Inc.

Optovue, Inc. is a privately held medical device company founded in 2003. Headquartered in Fremont, Calif., the company is dedicated to the advancement and commercializatio...

Optovue Incorporated

Optovue Incorporated is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities tha...

Optovue Inc.

RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corne...

More Information about "Optovue, Inc." on BioPortfolio

We have published hundreds of Optovue, Inc. news stories on BioPortfolio along with dozens of Optovue, Inc. Clinical Trials and PubMed Articles about Optovue, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Optovue, Inc. Companies in our database. You can also find out about relevant Optovue, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topic

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Corporate Database Quicklinks

Searches Linking to this Company Record